220 related articles for article (PubMed ID: 8418246)
1. Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
Schold SC; Herndon JE; Burger PC; Halperin EC; Vick NA; Cairncross JG; Macdonald DR; Dropcho EJ; Morawetz R; Bigner DD
J Clin Oncol; 1993 Jan; 11(1):77-83. PubMed ID: 8418246
[TBL] [Abstract][Full Text] [Related]
2. An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Halperin EC; Gaspar L; Imperato J; Salter M; Herndon J; Dowling S
Am J Clin Oncol; 1993 Aug; 16(4):277-83. PubMed ID: 8392285
[TBL] [Abstract][Full Text] [Related]
3. Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.
Schold SC; Mahaley MS; Vick NA; Friedman HS; Burger PC; DeLong ER; Albright RE; Bullard DE; Khandekar JD; Cairncross JG
J Clin Oncol; 1987 Mar; 5(3):464-71. PubMed ID: 3029339
[TBL] [Abstract][Full Text] [Related]
4. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.
Halperin EC; Herndon J; Schold SC; Brown M; Vick N; Cairncross JG; Macdonald DR; Gaspar L; Fischer B; Dropcho E; Rosenfeld S; Morowitz R; Piepmeier J; Hait W; Byrne T; Salter M; Imperato J; Khandekar J; Paleologos N; Burger P; Bentel GC; Friedman A
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(4):793-802. PubMed ID: 8598355
[TBL] [Abstract][Full Text] [Related]
5. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
[TBL] [Abstract][Full Text] [Related]
6. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558
[TBL] [Abstract][Full Text] [Related]
7. Sister chromatid exchange induction in patients with anaplastic gliomas undergoing treatment with radiation plus diaziquone or 1,3-bis(2-chloroethyl)-1-nitrosourea.
Kligerman AD; Erexson GL; Wilmer JL; Schold SC
Cancer Res; 1987 Jan; 47(2):631-5. PubMed ID: 3791247
[TBL] [Abstract][Full Text] [Related]
8. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ
Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540
[TBL] [Abstract][Full Text] [Related]
9. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.
Buckner JC; Schomberg PJ; McGinnis WL; Cascino TL; Scheithauer BW; O'Fallon JR; Morton RF; Kuross SA; Mailliard JA; Hatfield AK; Cole JT; Steen PD; Bernath AM
Cancer; 2001 Jul; 92(2):420-33. PubMed ID: 11466698
[TBL] [Abstract][Full Text] [Related]
10. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
Ali AN; Zhang P; Yung WKA; Chen Y; Movsas B; Urtasun RC; Jones CU; Choi KN; Michalski JM; Fischbach AJ; Markoe AM; Schultz CJ; Penas-Prado M; Garg MK; Hartford AC; Kim HE; Won M; Curran WJ
J Neurooncol; 2018 Mar; 137(1):39-47. PubMed ID: 29404979
[TBL] [Abstract][Full Text] [Related]
11. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Chang CH; Horton J; Schoenfeld D; Salazer O; Perez-Tamayo R; Kramer S; Weinstein A; Nelson JS; Tsukada Y
Cancer; 1983 Sep; 52(6):997-1007. PubMed ID: 6349785
[TBL] [Abstract][Full Text] [Related]
12. Intravenous BCNU and AZQ in patients with recurrent malignant gliomas.
Yung WK; Harris MI; Bruner JM; Feun LG
J Neurooncol; 1989 Sep; 7(3):237-40. PubMed ID: 2795118
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Raizer JJ; Malkin MG; Kleber M; Abrey LE
Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
[TBL] [Abstract][Full Text] [Related]
14. Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
Slagel DE; Feola J; Houchens DP; Ovejera AA
Cancer Res; 1982 Mar; 42(3):812-6. PubMed ID: 7059979
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.
Walker MD; Alexander E; Hunt WE; MacCarty CS; Mahaley MS; Mealey J; Norrell HA; Owens G; Ransohoff J; Wilson CB; Gehan EA; Strike TA
J Neurosurg; 1978 Sep; 49(3):333-43. PubMed ID: 355604
[TBL] [Abstract][Full Text] [Related]
16. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.
Selker RG; Shapiro WR; Burger P; Blackwood MS; Arena VC; Gilder JC; Malkin MG; Mealey JJ; Neal JH; Olson J; Robertson JT; Barnett GH; Bloomfield S; Albright R; Hochberg FH; Hiesiger E; Green S;
Neurosurgery; 2002 Aug; 51(2):343-55; discussion 355-7. PubMed ID: 12182772
[TBL] [Abstract][Full Text] [Related]
17. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy.
Prados MD; Scott C; Curran WJ; Nelson DF; Leibel S; Kramer S
J Clin Oncol; 1999 Nov; 17(11):3389-95. PubMed ID: 10550132
[TBL] [Abstract][Full Text] [Related]
18. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.
Weller M; Müller B; Koch R; Bamberg M; Krauseneck P;
J Clin Oncol; 2003 Sep; 21(17):3276-84. PubMed ID: 12947063
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
[TBL] [Abstract][Full Text] [Related]
20. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
Rajkumar SV; Buckner JC; Schomberg PJ; Cascino TL; Burch PA; Dinapoli RP
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):297-302. PubMed ID: 9457812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
